PRTA
PROTHENA CORP PUBLIC LTD COCompany Information
- Company Name
- PROTHENA CORP PUBLIC LTD CO
- CIK
- CIK0001559053
- Category
- Accelerated filer
- Ticker: Exchange
- PRTA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PRTA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-29
- Last sale
- 2026-07-29
- Shares purchased (TTM)
- 821,500
- Shares sold (TTM)
- 16,048
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 45,440,694
- Shares outstanding
- 52,145,000
- Ownership
- 87.14%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 8.74%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 288 | 329 | 308 | 331 | 371 | 418 | 471 | 519 | 564 | 547 | 619 | 671 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 5 | 5 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 10 | 8 | 9 | 14 | 18 | 14 | 16 | 22 | 18 | 14 | 13 | ||||||
| Assets Current | 292 | 339 | 315 | 340 | 385 | 436 | 485 | 535 | 586 | 566 | 639 | 691 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Restricted Cash Current | - | - | 0 | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 2 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 8 | 9 | 10 | 10 | 11 | 11 | 12 | 13 | 12 | 13 | ||||||
| Deferred Income Tax Assets Net | - | - | 0 | 0 | 0 | 45 | 43 | 41 | 39 | 37 | 34 | 30 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 6 | 10 | ||||||
| Assets Noncurrent | 11 | 11 | 12 | 13 | 14 | 59 | 62 | 60 | 60 | 57 | 57 | 56 | ||||||
| Assets | 303 | 350 | 327 | 353 | 399 | 495 | 547 | 595 | 646 | 623 | 696 | 747 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 4 | 6 | 11 | 12 | 16 | 8 | 10 | 9 | 14 | 25 | 19 | ||||||
| Deferred Revenue Current | 1 | 2 | 3 | 3 | 5 | 8 | 9 | 9 | 8 | - | 0 | 0 | ||||||
| Restructuring Reserve Current | 0 | 9 | 13 | 18 | 30 | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 2 | ||||||
| Other Liabilities Current | 5 | 10 | 12 | 8 | 6 | 9 | 16 | 14 | 11 | 9 | 16 | 14 | ||||||
| Liabilities Current | 12 | 33 | 41 | 51 | 68 | 48 | 49 | 46 | 47 | 43 | 57 | 53 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Deferred Revenue Noncurrent | - | - | 0 | 0 | 0 | 2 | 3 | 6 | 7 | 67 | 67 | 67 | ||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 5 | 6 | 7 | 8 | 8 | 9 | 10 | 10 | 11 | 9 | ||||||
| Liabilities Noncurrent | 4 | 5 | 5 | 6 | 7 | 9 | 12 | 14 | 17 | 78 | 78 | 76 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities | 16 | 37 | 46 | 58 | 75 | 58 | 60 | 61 | 64 | 121 | 135 | 130 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 1,619 | 1,626 | 1,626 | 1,619 | 1,612 | 1,600 | 1,589 | 1,578 | 1,567 | 1,554 | 1,541 | 1,529 | ||||||
| Retained Earnings Accumulated Deficit | -1,332 | -1,314 | -1,346 | -1,325 | -1,288 | -1,163 | -1,102 | -1,044 | -985 | -1,052 | -980 | -913 | ||||||
| Stockholders Equity | 287 | 313 | 280 | 295 | 324 | 438 | 487 | 534 | 582 | 502 | 561 | 617 | ||||||
| Liabilities And Stockholders Equity | 303 | 350 | 327 | 353 | 399 | 495 | 547 | 595 | 646 | 623 | 696 | 747 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 52 | 53 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | ||||||
| Shares Outstanding | 52 | 53 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 54 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPROTHENA CORP PUBLIC LTD CO (PRTA) — SEC Financial Statements & Analysis
PROTHENA CORP PUBLIC LTD CO (PRTA) is a pharmaceutical preparations company, incorporated in L2. PROTHENA CORP PUBLIC LTD CO trades on Nasdaq as: PRTA. PROTHENA CORP PUBLIC LTD CO (PRTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, PROTHENA CORP PUBLIC LTD CO carries a market cap of $510.50M, a P/E ratio of -11.60x, a P/B ratio of 1.78x, a P/S ratio of 9.36x, an enterprise value of $221.45M, and an EV/EBITDA multiple of -4.05x. On profitability, it posts an operating margin of -101.80%, a net margin of -80.67%, a Return on Equity (ROE) of -14.39%, and a Return on Assets (ROA) of -12.54%. Per share, it reports EPS of $-0.84, diluted EPS of $-0.84, free cash flow per share of $-1.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 427.32% year-over-year, net income growth of -85.48% year-over-year, and EPS growth of -85.01% year-over-year. On the balance sheet, it maintains a current ratio of 25.05x, a quick ratio of 24.72x, working capital of $280.36M, a debt-to-equity ratio of 0.05x, a debt ratio of 0.05, an interest coverage ratio of -5.06x, free cash flow of $-60.05M (TTM), and net debt of $-289.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $510.50M
- P/E TTM
- -11.60x
- EPS TTM
- $-0.84
- P/B TTM
- 1.78x
- ROE TTM
- -14.39%
- ROA TTM
- -12.54%
- Debt To Equity
- 0.05x
- Free Cash Flow TTM
- $-60.05M
- Net Revenue TTM Growth 1Y
- 427.32%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is PROTHENA CORP PUBLIC LTD CO in?
PROTHENA CORP PUBLIC LTD CO (PRTA) operates in the Pharmaceutical Preparations industry.
What exchange does PRTA trade on?
PROTHENA CORP PUBLIC LTD CO (PRTA) trades on the Nasdaq.
Where is PROTHENA CORP PUBLIC LTD CO incorporated?
PROTHENA CORP PUBLIC LTD CO is incorporated in Ireland.
When was PROTHENA CORP PUBLIC LTD CO (PRTA)'s most recent SEC filing?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is PRTA's market cap?
PROTHENA CORP PUBLIC LTD CO (PRTA) has a market capitalization of $510.50M as of 2026-06-30.
What is PRTA's EPS (earnings per share)?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s trailing twelve month EPS is $-0.84 as of 2026-06-30.
What is PRTA's ROE (return on equity)?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s trailing twelve month Return on Equity (ROE) is -14.39% as of 2026-06-30.
What is PRTA's ROA (return on assets)?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s trailing twelve month Return on Assets (ROA) is -12.54% as of 2026-06-30.
What is PRTA's EV/EBITDA?
PROTHENA CORP PUBLIC LTD CO (PRTA)'s trailing twelve month EV/EBITDA is -4.05x as of 2026-06-30.